Megan Brooks November 02, 2023 An investigational natural killer cell (NK) therapy has shown promise in the treatment of Alzheimer’s disease (AD), in a small phase 1 proof-of-concept clinical trial. SNK01, being developed by NKGen Biotech, is an autologous, nongenetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression. “When we give these enhanced...